Coyne Terrance P. — SEC insider filings
SEC reporting owner CIK 1814876. 35 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 35 filings on record, filed 2021-01-05 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 53 legs across 22 filings — 1,577,523 shares, $73,049,917 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: sale of 135,249 shares @ $68.87 ($9,314,342) in Royalty Pharma plc, filed 2026-11-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Royalty Pharma plc (RPRX) | EVP & CFO | 35 | — | 53 legs · 1,577,523 sh · $73,049,917 | 25 |
Insider filings — Coyne Terrance P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 135,249 @ $68.87 · Sale (S): 14,751 @ $68.30 · Sale (S): 90,165 @ $68.87 · Sale (S): 9,835 @ $68.30 · Sale (S): 7,122 @ $68.87 | EDGAR |
| 2026-11-06 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 7,122 @ $0 · Conversion (C): 150,000 @ $0 · Conversion (C): 100,000 @ $0 · Conversion (C): 15,000 (derivative) @ $0 · Conversion (C): 10,000 (derivative) @ $0 | EDGAR |
| 2026-08-17 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 9,230 @ $58.59 · Sale (S): 1,772 @ $59.14 | EDGAR |
| 2026-08-07 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 11,002 @ $0 · Gift (G): 18,500 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 64,399 @ $53.98 | EDGAR |
| 2026-05-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 24,263 @ $0 | EDGAR |
| 2026-04-30 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 32,916 @ $49.78 · Sale (S): 1,875 @ $49.78 | EDGAR |
| 2026-04-02 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 1,875 @ $48.33 · Sale (S): 32,916 @ $48.33 | EDGAR |
| 2026-03-25 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 32,916 @ $45.53 · Sale (S): 1,875 @ $45.53 | EDGAR |
| 2026-03-04 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 22,487 @ $46.67 · Sale (S): 10,429 @ $47.01 · Sale (S): 1,292 @ $46.67 · Sale (S): 583 @ $47.01 | EDGAR |
| 2026-02-25 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 32,916 @ $45.32 · Sale (S): 1,875 @ $45.32 | EDGAR |
| 2026-02-13 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 26,626 @ $0 | EDGAR |
| 2026-02-04 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 102,581 @ $42.08 · Sale (S): 108,759 @ $42.84 · Sale (S): 19,076 @ $43.29 · Sale (S): 5,843 @ $42.08 · Sale (S): 6,195 @ $42.84 · Sale (S): 1,087 @ $43.29 | EDGAR |
| 2026-01-23 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 65,832 @ $39.35 · Sale (S): 3,750 @ $39.35 | EDGAR |
| 2026-01-06 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 65,832 @ $38.42 · Sale (S): 3,750 @ $38.42 | EDGAR |
| 2025-12-17 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 65,832 @ $38.36 · Sale (S): 3,750 @ $38.36 | EDGAR |
| 2025-12-03 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 65,832 @ $39.87 · Sale (S): 3,750 @ $39.87 | EDGAR |
| 2025-11-26 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 55,146 @ $38.67 · Sale (S): 10,686 @ $37.96 · Sale (S): 3,126 @ $38.67 · Sale (S): 624 @ $37.96 | EDGAR |
| 2025-11-19 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 65,844 @ $39.30 · Sale (S): 3,750 @ $39.30 | EDGAR |
| 2025-11-07 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 6,168 @ $0 | EDGAR |
| 2025-08-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 3,696 @ $0 · Gift (G): 1,000 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,807,277 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 48,646 @ $0 | EDGAR |
| 2024-08-12 | 4 | Royalty Pharma plc (RPRX) | Gift (G): 2,000 (derivative) @ $0 | EDGAR |
| 2023-08-11 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 37,500 @ $30.72 · Sale (S): 37,500 @ $30.75 | EDGAR |
| 2023-08-08 | 4 | Royalty Pharma plc (RPRX) | Gift (G): 1,650 (derivative) @ $0 | EDGAR |
| 2023-07-14 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 37,500 @ $31.07 · Sale (S): 37,500 @ $30.93 | EDGAR |
| 2022-11-10 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 24,500 @ $43.47 | EDGAR |
| 2022-11-04 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 5,500 @ $43.06 | EDGAR |
| 2022-08-03 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 30,000 @ $43.19 | EDGAR |
| 2021-05-11 | 4 | Royalty Pharma plc (RPRX) | Conversion (C): 1,000,000 @ $0 · Conversion (C): 100,000 (derivative) @ $0 | EDGAR |
| 2021-03-05 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 29,820 @ $43.71 · Sale (S): 57,723 @ $45.09 · Sale (S): 11,001 @ $45.86 · Sale (S): 1,456 @ $46.83 | EDGAR |
| 2021-03-04 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 94,978 @ $46.89 · Sale (S): 5,022 @ $47.88 | EDGAR |
| 2021-01-05 | 4/A | Royalty Pharma plc (RPRX) | Conversion (C): 24,170 @ $0 · Grant/award (A): 2,605 (derivative) @ $0 · Conversion (C): 2,417 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Royalty Pharma plc (RPRX) | Conversion (C): 99,770 @ $0 · Conversion (C): 300,230 @ $0 · Conversion (C): 9,977 (derivative) @ $0 · Conversion (C): 30,023 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1814876 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs